3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Pheochromocytoma
3
Paraganglioma
3
Neuroendocrine Tumors
2
Meningioma
2
von Hippel-Lindau Disease
1
Thyroid cancer, Hurthle cell
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Metastatic Neuroendocrine Prostate Cancer
1
Kidney Neoplasms
1
Hypertension
1
Head and Neck Neoplasms
1
Ganglioneuroma
1
Ganglioneuroblastoma
1
Carcinoma, Neuroendocrine
1
Adenocarcinoma, Follicular
1
Interventions
pasireotide
1
lutetium Lu 177 dotatate
1
lanreotide
1
amino-acid, glucose, and electrolyte solution
1
Sunitinib
1
Octreotide
1
Everolimus
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
gallium Ga 68 dotatate
×
90 days
×
Clear all
No trials found.